Study: Prostate Cancer Drug Extends Life

Thursday, 26 May 2011 09:00 AM

The recently approved prostate cancer pill Zytiga is offering new hope for men with advanced disease.

A study published in the New England Journal of Medicine shows men who took the drug and who already underwent chemotherapy lived four months longer than those who took a placebo, WebMD.com reports.

The research involved 1,195 men with spreading prostate cancer that had progressed after chemotherapy. Those men who received steroid therapy along with the new pill survived for an average of 14.8 months, compared with 10.9 months for those who received a placebo and steroids. The results showed a 34 percent reduction in risk of dying.

Men taking the placebo were allowed to switch to Zytiga, which was approved by the Food and Drug Administration in April, before the study was completed because the survival extension was considered so significant.

This survival gain "means quite a bit," study researcher Dr. Howard I. Scher, chief of the genitourinary oncology service at Memorial Sloan-Kettering Cancer Center in New York City, tells WebMD.com. "These are a group of patients for whom there is no standard of care and it is particularly gratifying to see these results, to say the least."

To read the complete WebMD.com story, Go Here Now.

© HealthDay

1Like our page
Thursday, 26 May 2011 09:00 AM
Newsmax Media, Inc.

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved